SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
iSpecimen Inc. Common Stock
ISPC
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Last trade$0.5862
Day change-$0.0187 (-3.09%)
Day range$0.56 – $0.609
Volume38,374
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.51M
Price / earnings
—
Price / book
0.87×
Price / sales
3.24×
EV / sales
-6.23×
EV / EBITDA
0.35×
Profitability
Earnings per share
-$4.53
Return on assets
-154.47%
Return on equity
-657.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.82×
Quick ratio
0.82×
Cash ratio
0.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ISPC, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$151.94K
$156.01K
$51.76K
$106.59K
$713.14K
$1.06M
$1.48M
$2.66M
Cost of revenue
$83.29K
$84.41K
$598.84K
$204.59K
$444.18K
$657.28K
$1.32M
$1.55M
Gross profit
$68.65K
$71.6K
-$547.08K
-$98K
$268.96K
$400.23K
$151.35K
$1.11M
Selling, general and administrative
$986.97K
$2.22M
$1.98M
$2.56M
$1.21M
$1.11M
$5.53M
$2.28M
Research and development
$327.74K
$281.57K
$31.84K
$22.37K
$635.4K
$639.05K
$117.57K
$84.97K
Total operating expenses
$1.43M
$2.61M
$2.14M
$2.73M
$2.09M
$2.04M
$5.99M
$2.81M
Operating income
-$1.36M
-$2.54M
-$2.69M
-$2.83M
-$1.82M
-$1.64M
-$5.84M
-$1.71M
Interest expense
$0
-$1.25K
-$7.97K
-$2
$9.62K
-$20.49K
-$203.77K
-$7.36K
Income before taxes
-$1.36M
-$2.28M
-$5M
-$2.78M
-$1.05M
-$1.66M
-$6.05M
-$1.44M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.36M
-$2.28M
-$5M
-$2.78M
-$1.05M
-$1.66M
-$6.05M
-$1.44M
Net income attributable to common shareholders
-$1.36M
-$2.28M
-$5M
-$2.78M
-$1.05M
-$1.66M
-$6.05M
-$1.44M
EBITDA
-$1.16M
-$2.4M
-$2.28M
-$2.37M
-$1.39M
-$1.21M
-$5.29M
-$1.16M
Basic earnings per share
-$0.98
-$6.66
-$25.81
-$19.20
-$16.78
-$28.55
-$213.52
-$84.00
Diluted earnings per share
-$0.98
-$6.66
-$25.81
-$19.20
-$16.78
-$28.55
-$213.52
-$84.00
Recent news
Company coverage with links to the original publishers.
iSpecimen Inc. (Nasdaq: ISPC) closed a $5 million public offering consisting of 996,231 shares of common stock and pre-funded warrants to purchase 2,849,923 shares. The company plans to use proceeds for debt repayment, potential acquisitions, marketing, and working capital. E.F. Hutton & Co. served as the exclusive placement agent.
E.F. Hutton & Co. served as exclusive placement agent for iSpecimen Inc.'s $5 million public offering. This marks the third capital markets engagement between the two firms since December 2025. The capital will support iSpecimen's strategic priorities including liability repayment, potential acquisitions, marketing initiatives, and general corporate purposes.
E.F. Hutton & Co. acted as exclusive placement agent for iSpecimen Inc.'s $2.5 million private placement, which closed on May 11, 2026. This marks the second financing transaction between the two companies in six months, following a $5.5 million placement in December 2025. iSpecimen operates an online marketplace connecting researchers with biospecimen providers for medical research.
iSpecimen Inc. (Nasdaq: ISPC) announced a private placement offering of approximately $2.5 million in gross proceeds. The company will issue 488,281 shares at $5.12 per share, with net proceeds intended for working capital and marketing expenses. The offering is expected to close on May 11, 2026, subject to customary closing conditions and requires stockholder approval under Nasdaq Listing Rules.
iSpecimen Inc. (NASDAQ: ISPC) shares surged 56.19% in after-hours trading to $0.20 following the announcement of a direct supplier-to-customer shipping overhaul that reduces domestic transit times by 70-85%, cutting delivery from 7-14 days to 1-2 days. The company also expanded rare specimen sourcing partnerships across Europe. However, the stock remains down 90.84% over the past 12 months and closed the regular session at $0.13.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.